DK0784629T3 - Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser - Google Patents

Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser

Info

Publication number
DK0784629T3
DK0784629T3 DK95933489T DK95933489T DK0784629T3 DK 0784629 T3 DK0784629 T3 DK 0784629T3 DK 95933489 T DK95933489 T DK 95933489T DK 95933489 T DK95933489 T DK 95933489T DK 0784629 T3 DK0784629 T3 DK 0784629T3
Authority
DK
Denmark
Prior art keywords
inhibitors
metalloproteases
therapeutic use
peptidyl compounds
compounds
Prior art date
Application number
DK95933489T
Other languages
Danish (da)
English (en)
Inventor
John Montana
Andrew Douglas Baxter
David Alan Owen
Robert John Watson
Neil Phillipson
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420057A external-priority patent/GB9420057D0/en
Priority claimed from GBGB9504907.8A external-priority patent/GB9504907D0/en
Priority claimed from GBGB9509431.4A external-priority patent/GB9509431D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DK0784629T3 publication Critical patent/DK0784629T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052Val-amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95933489T 1994-10-05 1995-10-05 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser DK0784629T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9420057A GB9420057D0 (en) 1994-10-05 1994-10-05 Compounds
GBGB9504907.8A GB9504907D0 (en) 1995-03-10 1995-03-10 Compounds
GBGB9509431.4A GB9509431D0 (en) 1995-05-10 1995-05-10 Compounds
PCT/GB1995/002362 WO1996011209A1 (en) 1994-10-05 1995-10-05 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases

Publications (1)

Publication Number Publication Date
DK0784629T3 true DK0784629T3 (da) 1999-10-25

Family

ID=27267412

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95933489T DK0784629T3 (da) 1994-10-05 1995-10-05 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser

Country Status (19)

Country Link
US (2) US5994312A (ja)
EP (1) EP0784629B1 (ja)
JP (1) JP3787605B2 (ja)
CN (1) CN1193978A (ja)
AT (1) ATE179431T1 (ja)
AU (1) AU695796B2 (ja)
BR (1) BR9509237A (ja)
CA (1) CA2201639A1 (ja)
CZ (1) CZ288436B6 (ja)
DE (1) DE69509401T2 (ja)
DK (1) DK0784629T3 (ja)
ES (1) ES2133807T3 (ja)
FI (1) FI971412A0 (ja)
GR (1) GR3030751T3 (ja)
HU (1) HUT77282A (ja)
MX (1) MX9702487A (ja)
NO (1) NO971537L (ja)
PL (1) PL183510B1 (ja)
WO (1) WO1996011209A1 (ja)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
EP0824544B1 (en) * 1995-05-10 2003-04-16 Darwin Discovery Limited Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
US5981491A (en) * 1995-05-10 1999-11-09 Darwin Discovery Limited Peptidyl compounds and their therapeutic use
CA2219973A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptidyl compounds and their therapeutic use
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
CZ289711B6 (cs) * 1995-10-05 2002-03-13 Darwin Discovery Limited Thiosubstituované peptidy, jejich pouľití jako inhibitorů metaloproteináz a uvolňování TNFalfa a farmaceutický prostředek je obsahující
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
US6048841A (en) * 1995-11-22 2000-04-11 Darwin Discovery, Ltd. Peptidyl compounds
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
ATE359264T1 (de) 1996-01-23 2007-05-15 Shionogi & Co Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US6811995B1 (en) * 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
RU2221781C2 (ru) * 1996-07-22 2004-01-20 Монсанто Компани Тиолсульфоновые соединения в качестве ингибитора матриксной металлопротеазы и способы лечения
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
WO1998007421A1 (fr) 1996-08-16 1998-02-26 Ishihara Sangyo Kaisha, Ltd. Composition medicinale
TR199900477T2 (xx) * 1996-08-28 1999-06-21 Shionogi & Co. Ltd. Thiazolil-alanin art��� ihtiva eden yeni peptid t�revleri.
ES2184126T3 (es) * 1996-09-19 2003-04-01 Aventis Pharma Inc Derivados de 3-mercaptoacetilamino-1,5-sustituido-2-oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz.
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
BR9714142A (pt) * 1996-12-17 2000-02-29 Warner Lambert Co Uso de inibidores de metaloproteìnases matriciais para tratamento de distúrbios neurológicos e promoção de cicatrização de feridas
EP1366765A1 (en) * 1996-12-17 2003-12-03 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
ATE258063T1 (de) * 1997-03-03 2004-02-15 Darwin Discovery Ltd Selektive mmp inhibitoren mit verringerten nebenwirkungen
AU750130B2 (en) 1997-03-04 2002-07-11 Monsanto Company Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6034136A (en) 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
US6319902B1 (en) 1997-08-22 2001-11-20 Shionogi & Co., Ltd. Peptide derivatives having thiazolyl-alanine residue
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
EP1042290A1 (en) 1997-11-14 2000-10-11 G.D. SEARLE & CO. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer
CA2347911A1 (en) * 1998-10-23 2000-05-04 Darwin Discovery Limited Single morphic forms of known peptide metalloproteinase inhibitors
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
US6486193B2 (en) * 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
AU1926700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
KR20010102000A (ko) 1999-02-08 2001-11-15 윌리암스 로저 에이 술파마토 히드록삼산 메탈로프로테아제 억제제
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
NL1013404C2 (nl) * 1999-10-27 2001-05-01 Dsm Nv Werkwijze voor de bereiding van een dipeptide en tussenproduct in een dergelijke werkwijze.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
EP1282614B1 (en) 2000-05-15 2003-11-12 Darwin Discovery Limited Hydroxamic acid derivatives
DK1365787T3 (da) * 2000-08-25 2007-07-23 Res Corp Technologies Inc Anvendelse af aminosyre-holdige, krampestillende midler til behandling af smerte
EP1321151A4 (en) 2000-08-31 2009-07-15 Shionogi & Co MEANS FOR THE TREATMENT OF PARKINSON
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
CZ20032913A3 (cs) 2001-05-11 2004-05-12 Pharmaciaácorporation Aromatické sulfonhydroxamáty a jejich použití jako inhibitorů proteázy
KR20040023630A (ko) 2001-06-26 2004-03-18 아브게닉스, 인크. Opgl에 결합하는 항체
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
MXPA04010555A (es) 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
EP1515951A1 (en) * 2002-06-25 2005-03-23 Pharmacia Corporation Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
AU2003300379A1 (en) * 2002-12-27 2004-07-29 Angiotech Pharmaceuticals, Inc. Compositions and methods of using collagen and MMPI
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20040259744A1 (en) * 2003-12-19 2004-12-23 Meidong Yang Skin and hair cleansers containing sulfur
CN1950101B (zh) 2004-04-16 2011-03-30 舒沃茨药物股份公司 肽化合物用于预防和治疗慢性头痛的用途
NZ552651A (en) 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
AU2007260207B2 (en) 2006-06-15 2012-11-08 Ucb Pharma Gmbh Pharmaceutical composition with synergistic anticonvulsant effect
WO2008029168A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
WO2009048541A2 (en) * 2007-10-05 2009-04-16 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
CA2758322C (en) 2009-04-10 2019-04-02 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
WO2013016531A2 (en) * 2011-07-26 2013-01-31 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
WO2013039851A1 (en) 2011-09-12 2013-03-21 Mallinckrodt Llc Optical agents for imaging and visualization of matrix metalloproteinase enzymes
CN110143892B (zh) * 2019-06-21 2022-08-12 江苏豪森药业集团有限公司 莫沙必利中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113715A (en) * 1977-01-17 1978-09-12 E. R. Squibb & Sons, Inc. Amino acid derivatives
US4235885A (en) * 1979-06-25 1980-11-25 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
US4263293A (en) * 1980-05-30 1981-04-21 E. R. Squibb & Sons, Inc. Heterocyclic containing amides as inhibitors of mammalian collagenase
US4382081A (en) * 1981-06-12 1983-05-03 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
WO1988006890A1 (en) * 1987-03-17 1988-09-22 Research Corporation Technologies, Inc. Synthetic inhibitors of mammalian collagenase
AU2228292A (en) * 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
CA2170158A1 (en) * 1993-08-23 1995-03-02 Roy A. Black Inhibitors of tnf-alpha secretion
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds

Also Published As

Publication number Publication date
AU3612795A (en) 1996-05-02
FI971412A (fi) 1997-04-04
US6180611B1 (en) 2001-01-30
US5994312A (en) 1999-11-30
NO971537L (no) 1997-06-04
HUT77282A (hu) 1998-03-30
EP0784629A1 (en) 1997-07-23
BR9509237A (pt) 1997-10-21
DE69509401T2 (de) 1999-08-19
EP0784629B1 (en) 1999-04-28
MX9702487A (es) 1998-04-30
ES2133807T3 (es) 1999-09-16
CN1193978A (zh) 1998-09-23
FI971412A0 (fi) 1997-04-04
NO971537D0 (no) 1997-04-04
PL319503A1 (en) 1997-08-18
JPH10507170A (ja) 1998-07-14
CA2201639A1 (en) 1996-04-18
CZ288436B6 (en) 2001-06-13
AU695796B2 (en) 1998-08-20
DE69509401D1 (de) 1999-06-02
ATE179431T1 (de) 1999-05-15
CZ99697A3 (en) 1997-09-17
WO1996011209A1 (en) 1996-04-18
GR3030751T3 (en) 1999-11-30
JP3787605B2 (ja) 2006-06-21
PL183510B1 (pl) 2002-06-28

Similar Documents

Publication Publication Date Title
DK0784629T3 (da) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser
DK0728144T3 (da) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser
DK1109787T3 (da) Arylpiperaziner og deres anvendelse som metalloproteinaseinhiberende midler (MMP)
DK1001930T3 (da) N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
EA199700186A1 (ru) Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
TR200103493T2 (tr) Metaloproteaz önleyicileri
DK0859784T3 (da) Thiosubstituerede peptider som inhibitorer af metalloproteinaser og TNF-frigivelse
UY27972A1 (es) Derivados de hidantoína
DK0741694T3 (da) Phenyleddikesyrederivater, fremgangsmåder og mellemprodukter til deres fremstilling og midler indeholdende disse
NO996313L (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
IL123431A0 (en) Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (MMP) and/or tumour necrosis factor (TNF)
NO20012914L (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
DK1242410T3 (da) Nye forbindelser
ATE320422T1 (de) Metalloproteinase inhibitoren
NO20030675L (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
TR200202439T2 (tr) Sodyum hidrojen değiştirici tip 1 önleyici (NHE-1)
DE69828638D1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
ZA9810361B (en) Heterocyclic compounds having MMP and TNF inhibitory activity.
IT1264596B1 (it) Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi